By BullScreen Editorial Team 
Shares of Natco Pharma Ltd surged about 4% in today’s trading session after the company announced the launch of its generic semaglutide injection multi-dose vials in India. The stock hit a high of Rs 973, up from the previous close of Rs 937.05, with the company’s market capitalization standing at Rs 17,357 crore.
The new product, priced starting at Rs 1,290, is being introduced under the brand names Semanat 2 mg/1.5 ml, Semanat 4 mg/3 ml, and Semafull 8 mg/3 ml, with the highest strength priced at Rs 1,750. Natco Pharma received regulatory approval from CDSCO in February 2026 to manufacture and market the drug in both multi-dose vials and pen devices.
Industry analysts point to the affordability of the product as a key driver of investor optimism. Natco’s multi-dose vials are reportedly 70% cheaper than pen devices and 90% lower than the innovator’s brand, potentially expanding access for chronic users, including diabetes patients. The launch also gives Natco an early-mover advantage, entering the market on Day 1 of the patent expiry.
The company plans to launch pen devices in April 2026 and is open to co-marketing agreements with third parties, a strategy that could accelerate market penetration. Investors see this move as a step toward diversifying beyond Natco’s traditional oncology-focused portfolio and tapping into the growing diabetes management segment.
Financially, Natco Pharma has shown strong growth. Revenue from operations rose 36% year-on-year to Rs 647 crore in Q3 FY26 from Rs 475 crore in Q3 FY25. Net profit increased to Rs 151 crore from Rs 132 crore over the same period. With a price-to-earnings ratio of 11.1 versus the industry average of 27.2, the stock remains attractively valued, bolstered by the recent product launch and growth prospects.